Pharmacokinetic/pharmacodynamic modeling and simulation to determine effective dosage regimens for doripenem

Journal of Pharmaceutical Sciences

Volumn 99, Issue 5, 2010, Pages 2483-2491

  Katsube, Takayuki ^a,b   Yano, Yoshitaka ^c   Wajima, Toshihiro ^a   Yamano, Yoshinori ^a   Takano, Mikihisa ^b  

^a SHIONOGI AND CO LTD   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Mathematical model; Pharmacodynamics; Pharmacokinetic pharmacodynamic models; Pharmacokinetics; Simulations

Indexed keywords

DORIPENEM;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL COUNT; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; HUMAN; IN VITRO STUDY; KIDNEY FUNCTION; MONTE CARLO METHOD; NONHUMAN; PROBABILITY; PSEUDOMONAS AERUGINOSA; TREATMENT DURATION;

EID: 77951288990     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21997     Document Type: Article

References (43)

1. Sheiner LB, Steimer JL. 2000. Pharmacokinetic/pharmacodynamic modeling in drug development. Annu Rev Pharmacol Toxicol 40:67-95.
2. Chien JY, Friedrich S, Heathman MA, de Alwis DP, Sinha V. 2005. Pharmacokinetics/pharmacodynamics and the stages of drug development: Role of modeling and simulation. AAPS J 7:E544-E559.
3. Müller M, Müller-Zellenberg U, Hochhaus G, Derendorf H. 2001. Current concepts in pharmacokinetics and their implications for clinical medicine. Wien Klin Wochenschr 113:566-572. (Pubitemid 33607960)
4. Mattie H. 1981. Kinetics of antimicrobial action. Rev Infect Dis 3:19-27.
5. Tsuji A, Hamano S, Asano T, Nakashima E, Yamana T, Mitsuhashi S. 1984. Microbial kinetics of β-lactam antibiotics against Escherichia coli. J Pharm Sci 73:1418-1422. (Pubitemid 14021897)
6. Hamano S, Tsuji A, Asano T, Tamai I, Nakashima E, Yamana T, Mitsuhashi S. 1984. Kinetic analysis and characterization of the bacterial regrowth after treatment of Escherichia coli with β-lactam antibiotics. J Pharm Sci 73:1422-1427. (Pubitemid 14021898)
7. Zhi J, Nightingale CH, Quintiliani R. 1988. Microbial pharmacodynamics of piperacillin in neutropenic mice of systematic infection due to Pseudomonas aeruginosa. J Pharmacokinet Biopharm 16:355-375.
8. Carret G, Flandrois JP, Lobry JR. 1991. Biphasic kinetics of bacterial killing by quinolones. J Antimicrob Chemother 27:319-327.
9. Li RC, Nix DE, Schentag JJ. 1994. Pharmacodynamic modeling of bacterial kinetics: β-lactam antibiotics against Escherichia coli. J Pharm Sci 83:970-975.
10. Czock D, Keller F. 2007. Mechanism-based pharmacokinetic-pharmacodynamic modeling of antimicrobial drug effects. J Pharmacokinet Pharmacodyn 34:727-751. (Pubitemid 350165274)
11. Nielsen EI, Viberg A, Löwdin E, Cars O, Karlsson MO, Sandström M. 2007. Semimechanistic pharmacokinetic/pharmacodynamic model for assessment of activity of antibacterial agents from time-kill curve experiments. Antimicrob Agents Chemother 51:128-136. (Pubitemid 46047697)
12. Tam VH, Schilling AN, Poole K, Nikolaou M. 2007. Mathematical modelling response of Pseudomonas aeruginosa to meropenem. J Antimicrob Chemother 60:1302-1309. (Pubitemid 350168327)
13. Bulitta JB, Ly NS, Yang JC, Forrest A, Jusko WJ, Tsuji BT. 2009. Development and qualification of a pharmacodynamic model for the pronounced inoculum effect of ceftazidime against Pseudomonas aeruginosa. Antimicrob Agents Chemother 53:46-56.
14. Yano Y, Oguma T, Nagata H, Sasaki S. 1998. Application of logistic growth model to pharmacodynamic analysis of in vitro bactericidal kinetics. J Pharm Sci 87:1177-1183. (Pubitemid 28455605)
15. Robertson TB. 1923. The chemical basis of growth and senescence. Philadelphia and London: Lippincott.
16. Jusko WJ. 1973. A pharmacodynamic model for cell-cycle specific chemotherapeutic agents. J Pharmacokinet Biopharm 1:175-200.
17. Katsube T, Yano Y, Yamano Y, Munekage T, Kuroda N, Takano M. 2008. Pharmacokinetic-pharmacodynamic modeling and simulation for bactericidal effect in an in vitro dynamic model. J Pharm Sci 97:4108-4117.
18. Katsube T, Yamano Y, Yano Y. 2008. Pharmacokinetic-pharmacodynamic modeling and simulation for in vivo bactericidal effect in murine infection model. J Pharm Sci 97:1606-1614.
19. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. 1993. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 37:1073-1081. (Pubitemid 23141323)
20. Moise PA, Forrest A, Bhavnani SM, Birmingham MC, Schentag JJ. 2000. Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus. Am J Health Syst Pharm 57:S4-S9.
21. Dagan R, Klugman KP, Craig WA, Baquero F. 2001. Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy. J Antimicrob Chemother 47:129-140. (Pubitemid 32149516)
22. Montgomery MJ, Beringer PM, Aminimanizani A, Louie SG, Shapiro BJ, Jelliffe R, Gill MA. 2001. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis. Antimicrob Agents Chemother 45:3468-3473. (Pubitemid 33107864)
23. Nicolau DP, Ambrose PG. 2001. Pharmacodynamic profiling of levofloxacin and gatifloxacin using Monte Carlo simulation for community-acquired isolates of Streptococcus pneumoniae. Am J Med 111:13S-18S.
24. Andes D, Craig WA. 2002. Animal model pharmacokinetics and pharmacodynamics: A critical review. Int J Antimicrob Agents 19:261-268. (Pubitemid 34308974)
25. Tessier PR, Kim MK, Zhou W, Xuan D, Li C, Ye M, Nightingale CH, Nicolau DP. 2002. Pharmacodynamic assessment of clarithromycin in a murine model of pneumococcal pneumonia. Antimicrob Agents Chemother 46:1425-1434. (Pubitemid 34415324)
26. Drusano GL. 2003. Prevention of resistance: A goal for dose selection for antimicrobial agents. Clin Infect Dis 36:S42-S50.
27. Tanaka T, Aizawa K, Shimuzu A, Sakakibara S, Watabe H, Totsuka K. 2004. Optimization of dose and dose regimen of biapenem based on pharmacokinetic and pharmacodynamic analysis. J Infect Chemother 10:76-85. (Pubitemid 38590729)
28. Li C, Kuti JL, Nightingale CH, Nicolau DP. 2006. Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients. J Clin Pharmacol 46:1171-1178. (Pubitemid 44387417)
29. Kim A, Banevicius MA, Nicolau DP. 2008. In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. Antimicrob Agents Chemother 52:2497-2502.
30. Fujimura T, Kimura Y, Yoshida I, Higashiyama I, Jinushi Y, Munekage T, Kuroda N, Doi M, Nishikawa T, Yamano Y. 2005. In vitro antibacterial activity of doripenem, a novel parenteral carbapenem. Jpn J Chemother 53:57-70.
31. Kuroda N, Munekage T, Yamano Y. 2005. Bactericidal activity of DRPM using in vitro pharmacodynamic models. Jpn J Chemother 53:96-103. (Pubitemid 41093794)
32. Nakashima M, Oguma T. 2005. Phase I study of doripenem, a new carbapenem antibiotic for injection in healthy volunteers. Jpn J Chemother 53: 104-123. (Pubitemid 41093795)
33. Beal SL, Sheiner LB. 1988-2006. NONMEM Users Guide. San Francisco: University of California.
34. Cockcroft DW, Gault MH. 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41.
35. Uehara S, Murao W, Seno Y, Andoh E, Monden K, Kariyama R, Tsugawa M, Nakashima M, Kumon H. 2005. Pharmacokinetics of doripenem in patients with renal dysfunction. Jpn J Chemother 53:130-135. (Pubitemid 41102109)
36. Chastre J, Fagon JY, Bornet-Lecso M, Calvat S, Dombret MC, al Khani R, Basset F, Gibert C. 1995. Evaluation of bronchoscopic techniques for the diagnosis of nosocomial pneumonia. Am J Respir Crit Care Med 152:231-240.
37. Nix DE, Goodwin SD, Peloquin CA, Rotella DL, Schentag JJ. 1991. Antibiotic tissue penetration and its relevance: Models of tissue penetration and their meaning. Antimicrob Agents Chemother 35:1947-1952.
38. Nix DE, Goodwin SD, Peloquin CA, Rotella DL, Schentag JJ. 1991. Antibiotic tissue penetration and its relevance: Impacts of tissue penetration on infection response. Antimicrob Agents Chemother 35:1953-1959.
39. Kneer J. 1993. Relevance of antibiotics tissue penetration in treating respiratory tract infections. Respiration 60:32-37. (Pubitemid 23088656)
40. Deguchi Y, Terasaki T, Yamada H, Tsuji A. 1992. An application of microdialysis to drug tissue distribution study: In vivo evidence for free-ligand hypothesis and tissue binding of β-lactam antoibiotics in interstitial fluids. J Pharmacobiodyn 15:79-89.
41. Araki H, Ogake N, Tsuneda R, Minami S, Watanabe Y, Tamai I, Tsuji A. 2002. Muscle distribution of antimicrobial agents after a single intravenous administration to rats. Drug Metab Pharmacokinet 17:237-244.
42. Liu P, Muller M, Derendorf H. 2002. Rational dosing of antibiotics: The use of plasma concentrations versus tissue concentrations. Int J Antimicrob Agents 19:285-290. (Pubitemid 34308976)
43. Liu P, Fuhrherr R, Webb AI, Obermann B, Derendorf H. 2005. Tissue penetration of cefpodoxime into the skeletal muscle and lung in rats. Eur J Pharm Sci 25:439-444. (Pubitemid 40853871)